Blood coagulation unaffected by ozonated autohemotherapy in patients on maintenance hemodialysis

Arch Med Res. 2006 Nov;37(8):1034-7. doi: 10.1016/j.arcmed.2006.06.006.

Abstract

Background: Ozonated autohemotherapy (O(3)-AHT) is a clinically useful therapeutic procedure in hemodialyzed patients with peripheral arterial occlusive disease (PAOD). The majority of patients on dialysis are in a hypercoagulable state. Thrombotic complications are the major cause of morbidity and mortality in hemodialyzed patients. Effects of O(3)-AHT on blood coagulation were evaluated in 11 hemodialyzed patients affected by PAOD.

Methods: We performed an oxygen-controlled, crossover study in which nine sessions of autohemotherapy with oxygen administration (AHT) as a control were followed by nine sessions of O(3)-AHT. Blood coagulation was assessed by antithrombin III, activated partial thromboplastin time, prothrombin time, D-dimer and fibrinogen plasma concentrations.

Results: The extents of all the measured parameters after nine sessions of O(3)-AHT did not differ statistically from the values after nine sessions of AHT. Similarly, there were no differences in the measured variables after the first session of O(3)-AHT as compared to the values before therapy. We did not observe any thrombotic accidents during the study.

Conclusions: O(3)-AHT with ozone concentration of 50 microg/mL and citrate as an anticoagulant does not influence blood coagualation parameters in hemodialyzed patients with PAOD.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Arterial Occlusive Diseases / drug therapy
  • Arterial Occlusive Diseases / therapy*
  • Blood Coagulation / drug effects*
  • Blood Coagulation Tests
  • Blood Transfusion, Autologous / methods*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Ozone / therapeutic use*
  • Peripheral Vascular Diseases / drug therapy
  • Peripheral Vascular Diseases / therapy*
  • Renal Dialysis
  • Treatment Failure

Substances

  • Ozone